Fed. Circ. Teva Ruling May Shake Up Skinny Label Strategies
Generic and biosimilar companies often employ a congressionally approved skinny label strategy to carve out patented method-of-use indications to launch generic drugs that have noninfringing uses....To view the full article, register now.
Already a subscriber? Click here to view full article